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Background: Granulomatous disease is reported in at least 8–20% of patients with
common variable immunodeficiency (CVID). Granulomatous disease mainly affects the
lungs, and is associated with significantly higher morbidity and mortality. In half of patients
with granulomatous disease, extrapulmonary manifestations are found, affecting e.g. skin,
liver, and lymph nodes. In literature various therapies have been reported, with varying effects
on remission of granulomas and related clinical symptoms. However, consensus
recommendations for optimal management of extrapulmonary granulomatous disease are
lacking.
Objective: To present a literature overview of the efficacy of currently described therapies
for extrapulmonary granulomatous disease in CVID (CVID+EGD), compared to known
treatment regimens for pulmonary granulomatous disease in CVID (CVID+PGD).
Methods: The following databases were searched: Embase, Medline (Ovid), Web-of-
Science Core Collection, Cochrane Central, and Google Scholar. Inclusion criteria were 1)
CVID patients with granulomatous disease, 2) treatment for granulomatous disease
reported, and 3) outcome of treatment reported. Patient characteristics, localization of
granuloma, treatment, and association with remission of granulomatous disease were
extracted from articles.
Results: We identified 64 articles presenting 95 CVID patients with granulomatous disease,
wherein 117 different treatment courses were described. Steroid monotherapy was most
frequently described in CVID+EGD (21 out of 53 treatment courses) and resulted in remission
in 85.7% of cases. In CVID+PGD steroid monotherapy was described in 15 out of 64
treatment courses, and was associated with remission in 66.7% of cases. Infliximab was
reported in CVID+EGD in six out of 53 treatment courses and was mostly used inorg December 2020 | Volume 11 | Article 6063891
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Frontiers in Immunology | www.frontiersin.granulomatous disease affecting the skin (four out of six cases). All patients (n = 9) treated with
anti-TNF-a therapies (infliximab and etanercept) showed remission of extrapulmonary
granulomatous disease. Rituximab with or without azathioprine was rarely used for CVID
+EGD, but frequently used in CVID+PGD where it was associated with remission of
granulomatous disease in 94.4% (17 of 18 treatment courses).
Conclusion: Although the number of CVID+EGD patients was limited, data indicate that
steroid monotherapy often results in remission, and that anti-TNF-a treatment is effective
for granulomatous disease affecting the skin. Also, rituximab with or without azathioprine
was mainly described in CVID+PGD, and only in few cases of CVID+EGD.Keywords: common variable immune deficiency, granulomatous disease, lung, immunosuppressive
therapy, extrapulmonaryINTRODUCTION
Common variable immunodeficiency (CVID) is a primary
antibody deficiency with a heterogeneous clinical phenotype.
It is characterized by a marked decrease in levels of
immunoglobulin (Ig) G with decreased levels of IgA and/or
IgM, and an impaired response to immunization (1, 2).
Recurrent infections, mainly by encapsulated bacteria,
are a clinical hallmark in the majority of CVID patients.
Furthermore, large cohort studies showed that up to 74% of
CVID patients suffer from non-infectious complications (3, 4).
These include granulomatous disease, progressive lung disease,
autoimmunity (AI), enteropathy, liver disease, and malignancy
(3, 4). These non-infectious complications are associated with
deleterious effects on disease burden and survival, as the presence
of one or more of these non-infectious complications results in
~11 times higher risk of death compared to CVID patients with
infectious complications only (5).
Granulomatous disease is reported in 8–20% of CVID
patients (3, 4, 6), although it is generally assumed that the
presence of granulomatous disease is underreported. The
trigger for granuloma formation in CVID remains elusive. The
long-standing observation of an increased incidence of
autoimmune disease in CVID patients with granulomatous
disease could suggest an immune dysregulated milieu that
supports granuloma formation (7, 8). Various infectious
triggers have been reported as well. Human Herpes virus-8 and
Toxoplasma gondii are reported in relation to granuloma
formation in CVID (9, 10). More recently, Rubella positive M2
macrophages were identified in granulomas in a patient with
CVID that received a Rubella vaccine during childhood (11).
However, reports are limited or could not be reproduced and
further research is required to better understand thelytic anemia; BM, Bone marrow; CNS,
n variable immune deficiency; EGD,
se; GI, Gastro intestinal; GLILD,
lung disease; HSCT, Hematopoietic
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org 2pathogenesis of granulomatous disease in CVID. In CVID
patients, granulomatous disease mainly affects the lungs,
followed by lymph nodes (LN) and liver (3, 8). Granulomatous
disease of the lungs can be accompanied by interstitial
lymphocytic infiltrates, referred to as granulomatous
lymphocytic interstitial lung disease (GLILD), a condition not
exclusively observed in CVID. The lungs as site for complications
in primary antibody deficiencies, both infectious or non-
infectious related, is extensively discussed in the paper by
Bauman et al. (12). They highlight the heterogeneity in
diagnostic procedures and lack of guidelines for the treatment
of non-infectious complications, including GLILD, in primary
antibody deficiencies such as CVID. GLILD is a severe
complication, as shown by Bates et al. as they observed GLILD
in CVID to be associated with a 50% reduction of survival
probability when compared to CVID patients without this
complication (13). Over the past years, there has been much
focus on the diagnostic process and treatment of granulomatous
disease affecting the lungs (14). However, extrapulmonary
granulomatous disease is reported in about half of the patients
with granulomatous disease, making this subgroup at least as
important (3). Granulomatous lesions are reported in the LN,
liver, spleen, gastrointestinal tract (GI tract), bone marrow (BM),
skin, eyes, central nervous system (CNS), parotid gland, and
kidneys (7, 15–20). Interestingly, patients with extrapulmonary
granulomatous disease have a higher incidence of autoimmune
diseases compared to patients with granuloma restricted to the
lungs (7, 15).
Immunoglobulin replacement therapy (IgRT) is one of the
cornerstones of therapy in CVID, and has reduced the risk of
severe infectious complications (21). A protective effect of IgRT
on development of autoimmune disease, including autoimmune
hemolytic anemia (AIHA) and immune thrombocytopenia
(ITP), has been proposed (22). Optimizing treatment of
granulomatous disease is amongst the major challenges in
current clinical practice for CVID patients. Various therapies for
granulomatous disease, varying from classical immunosuppressive
agents, including steroids, and disease modifying anti-rheumatic
drugs (DMARDs), to more specific biologics such as rituximab,
have been reported; each with varying effects on remission of
granulomatous lesions and clinical improvement (23). Moreover,December 2020 | Volume 11 | Article 606389
van Stigt et al. Effective Treatment for Granulomatous CVIDthere is a diversity of combinations of immunosuppressive
treatments, resulting in a diverse group of multi-drug
treatment regimens.
Over the past decades, many reports have been published
containing valuable information regarding treatment of
granulomatous disease in CVID. With this systematic review,
we aim to provide an overview of the currently described
treatment regimens for granulomatous disease in genetically
undefined CVID with a special focus on treatment for
extrapulmonary granulomatous manifestations, and to report
which of these treatments are associated with remission of
granulomatous disease. We compared treatment regimens for
extrapulmonary granulomatous disease with regimens used in
granulomatous disease with lung involvement. Taking
these efforts together, we aim to elucidate which treatmentFrontiers in Immunology | www.frontiersin.org 3regimens are associated with remission of extrapulmonary
granulomatous disease.METHODS
Search Strategy and Article Identification
We performed a systematic search to identify all manuscripts
that describe the effect of drug therapy on clinical outcome of
granulomatous disease in CVID patients. The following
databases were used: Embase, Medline(Ovid), Web-of-Science
Core Collection, Cochrane Central, and Google Scholar, using
specific search strings per database (Table 1, Figure 1). Only
English-language peer-reviewed articles were included,
conference abstracts were excluded. On December 5th 2019,TABLE 1 | Overview of databases and search strings.
Database Search string
Embase.com (‘granuloma’/exp OR (granulom*):ab,ti,kw) AND (‘common variable immunodeficiency’/de OR (CVID* OR ((variable*) NEAR/3 (immunodefi* OR
agammaglobulinaem* OR hypogammaglobulinaem* OR hypogammaglobulinem* OR immune*-deficien*))):ab,ti,kw) NOT ([Conference Abstract]/lim) AND
[ENGLISH]/lim
Medline(Ovid) (exp “Granuloma”/OR (granulom*).ab,ti,kw.) AND (“Common Variable Immunodeficiency”/OR (CVID* OR ((variable*) ADJ3 (immunodefi* OR
agammaglobulinaem* OR hypogammaglobulinaem* OR hypogammaglobulinem* OR immune*-deficien*))).ab,ti,kw.) NOT (news OR congres* OR




TS=(((granulom*)) AND ((CVID* OR ((variable*) NEAR/2 (immunodefi* OR agammaglobulinaem* OR hypogammaglobulinaem* OR hypogammaglobulinem*
OR immune*-deficien*))))) AND DT=(Article OR Review) AND LA=(English)
Cochrane
Central
((granulom*):ab,ti,kw) AND ((CVID* OR ((variable*) NEAR/3 (immunodefi* OR agammaglobulinaem* OR hypogammaglobulinaem* OR
hypogammaglobulinem* OR immune* NEXT deficien*))):ab,ti,kw)
Google
Scholar
Granuloma “Common Variable Immunodeficiency”|CVID lung|pulomonaryFIGURE 1 | PRISMA flow diagram. PRISMA diagram showing search strategy and inclusion process of articles. Common variable immune deficiency (CVID).December 2020 | Volume 11 | Article 606389
van Stigt et al. Effective Treatment for Granulomatous CVIDafter correcting for duplicate findings, a total of 644 articles was
obtained for initial screening for eligibility (Table 2). An update
on the performed systematic search was performed July 14th
2020, obtaining 65 articles.
Eligibility Screening
Of these 709 (644 + 65) articles, title and abstract were screened
for eligibility by two independent reviewers (HIJ and AS), with a
third reviewer (VD) being involved when a discrepancy existed
between the two primary reviewers. Articles were considered to
be eligible when the title and/or abstract and/or keywords
referred to the effect of drug therapy on granulomatous disease
in CVID patients. In case the abstract, title, or keywords did not
suggest that the manuscript focused on CVID, granulomatous
disease, drug therapy, and effect on clinical outcome, the article
was excluded. For articles where no abstract was available, such
as letters, full text articles were screened for eligibility. Hereby,
196 (185 + 11) articles were selected.
Article Selection, Quality Assessment, and
Final Inclusion
The selected 196 articles were used for full in-depth reading by
the two independent reviewers (HIJ, AS). Articles were included
when the following inclusion criteria were met: 1) CVID patients
with granulomatous disease, objectified prior to treatment by
clinician via biopsy/radiographic imaging/functional analysis
(pulmonary function testing, ocular examination)/clinical
assessment, 2) treatment for granulomatous disease reported,
and 3) outcome of treatment evaluated via radiographic
imaging/functional testing/clinical assessment. Exclusion
criteria were: 1) papers not describing CVID, 2) not about
granulomatous disease, 3) patients with genetic defects
reported, 4) no therapy administered for granulomatous
disease, or 5) PDF not obtainable (Figure 1). Articles
describing sarcoidosis in CVID patients, or describing CVID
patients with sarcoidosis-like granulomatous disease, were
included in the analysis. Hereby, 76 articles were included.
Next, quality assessment was performed. For included case-
control studies (n = 1), the Newcastle-Ottawa Quality
Assessment Scale for Case Control Studies was used (http://
www.ohri.ca/programs/clinical_epidemiology/oxford.asp,
Supplemental Table 1). For case reports and case series (n = 75),
the assessment tool described by Murad et al. was used (https://
ebm.bmj.com/content/23/2/60 Supplemental Table 2) (24).
Articles with a poor quality score (≤2) were excluded for data
extraction. By cross-reference checking, 14 additional articlesFrontiers in Immunology | www.frontiersin.org 4were identified. After eligibility screening and in-depth reading,
three of these 14 manuscripts were of sufficient quality and
included. Hereby, 64 articles were finally included in this
systematic review and used for data extraction and analysis
(Figure 1, Supplemental Table 3).
Data Extraction and Data Analysis
Of the 64 articles finally included, reported study characteristics
and outcome measures were collected and summarized
(Supplemental Table 4). A total of 95 CVID cases with
granulomatous disease were used for further analysis. Since we
aimed to examine whether there was a difference regarding
treatment and treatment efficacy between CVID patients with
extrapulmonary granulomatous disease (CVID+EGD) and
CVID patients with pulmonary granulomatous disease (CVID
+PGD), patients were categorized based on granuloma locations
reported: CVID+EGD for patients with exclusively
extrapulmonary granuloma, and CVID+PGD for patient with
pulmonary granuloma (with or without granuloma at
other sites).
Treatment regimens and effect on granulomatous disease
were extracted for each case. In various reported cases,
multiple treatment regimens were administered. When
multiple treatment regimens were applied for granulomatous
disease within one patient at different time points, the effect of
the treatment regimens was considered separately. The efficacy of
a specific treatment regimen, i.e. the association with remission
of granulomatous disease, was evaluated per treatment course of
this treatment regimen. The efficacy of treatment regimens was
determined based on either one or more of the following
reported findings described in the included articles: 1) reported
improvement in clinical presentation, 2) reported improvement
of radiological findings, 3) reported improvement of specific
function testing, such as lung function testing (for lung
granulomatous disease) or ocular examination (for
granulomatous disease affecting the eye). Per treatment
regimen, the number of courses reported and the number of
courses associated with remission were scored. In some cases,
administration of IgRT as additional therapy was reported.
When IgRT was initiated simultaneously with therapy for
granulomatous disease, IgRT was considered part of the
treatment regimen for granulomatous disease, as it could not
be ruled out that IgRT had an effect on granulomatous disease.
When IgRT was started before the treatment regimen aimed at
granulomatous disease, IgRT was not considered as treatment of
granulomatous disease.TABLE 2 | Overview of database and output of search.
Database Number of references Number of references after duplication
Embase.com 414 407
Medline(Ovid) 303 31
Web-of-Science Core Collection 381 131
Cochrane Central 9 6
Google Scholar 200 69
Total 5th of December 2020 1,307 644
Total updated search 14th of July 2020 65
Final total references screened 709December 2020 | Volume 11 | Article 606389
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Study Selection and Literature Cases
Characteristics
After searching databases, 709 articles were screened for
eligibility. Full text reading and quality assessment resulted in
64 articles for data extraction (Figure 1, Supplemental Tables 1–
4). From the 64 articles, a literature derived cohort of 95 patients
was obtained (Table 3). The cases were divided in two groups: 1)
CVID patients with extrapulmonary granulomatous disease only
(CVID+EGD; n = 44; 46.3%) and 2) CVID patients with
pulmonary granulomatous disease (CVID+PGD; N = 51;
53.7%) (Table 3). The overall ratio female/male was 2.2
(female n = 65; male n = 30), with a slightly higher ratio in the
CVID+PGD group versus the CVID+EGD group (2.6 vs 1.8,
respectively). The average age, based on age reported in article or
age when CVID was diagnosed, was 34.3 with a range 2–72 years.
In 83.2% (79 out of 95) of the patients, biopsy was obtained as
part of the diagnostic work-up for granulomatous CVID. In the
remaining 16 cases, clinical assessment, ocular examination,
(HR)CT or MRI were used to diagnose granulomatous disease.
In 63.2% of all cases (60 of 95), we were able to determine
whether granulomatous disease was present before or after CVID
was diagnosed. In 36.7% (22 of 60) of the patients,
granulomatous disease was diagnosed before the diagnosis of
CVID. In the CVID+EGD group in 30.0% of patients (9 out of 30
patients) granulomatous disease was diagnosed before diagnosis
of CVID, while in the CVID+PGD group this was 43.3% (13 out
of 30 patients). Within this literature derived cohort the lungs,
skin, LN, liver, eye, spleen, intestines, kidneys, conjunctiva, CNS,
and vocal cords were affected by granulomatous disease (Table 4,
Supplemental Table 5). Of note, within one patient multiple
organs could be involved (Supplemental Table 5). Overall,
pulmonary granulomatous disease was the most frequently
affected location (n = 51), followed by skin (n = 24) and LN
(n = 20) (Table 4).Frontiers in Immunology | www.frontiersin.org 5Administered Treatment Regimens in
Granulomatous Disease in CVID
Steroids
Steroid therapy was the most frequently reported treatment
regimen for granulomatous disease in CVID (Tables 5 and 6).
For CVID+EGD, steroid monotherapy was the most frequently
reported regimen (21 of 53 treatment courses), with 85.7% of
treatment courses scored as effective (Table 5) (17, 19, 20, 25–
40). For CVID+PGD, steroid monotherapy also was the most
frequently reported treatment regimen (15 of 64 treatment
courses); 66.7% of these treatment courses were associated with
remission of granulomatous disease (Table 6) (29, 41–50). Apart
frommonotherapy, steroids were frequently prescribed as part of
a treatment regimen containing one or more other drugs, both in
CVID+EGD and CVID+PGD. However, the duration, type, and
doses administered varied between the different studies. Overall,
these results suggest that steroid therapy is a beneficial
therapeutic option, either as monotherapy or as part of
combination therapy, for granulomatous disease in CVID.TABLE 3 | Characteristics of 96 literature cases derived from 64 articles.
Characteristics included literature cases Total
cases




Number of patients 95 (100%) 44 (46.3%) 51 (53.7%)
Ratio female/male 2.2 (65/30) 1.8 (28/16) 2.6 (37/14)
Age of diagnosis CVID or age reported in article:
• Average
34.3 35.0 33.7
• Min. of age 2 4 2
• Max. of age 72 72 68




37 (84.1% of 44) 42 (82.4% of 51)
Timing diagnosis granuloma vs diagnosis CVID known 60 (63.2%
of 95)
30 (68.2% of 44) 30 (58.8% of 51)
Granuloma diagnosed before diagnosis CVID 22 (36.7%) 9 (30.0%) 13 (43.3%)
Granuloma diagnosed after diagnosis CVID 38 (63.3%) 21 (70.0%) 17 (56.6%)
Timing diagnosis granuloma vs diagnosis CVID not
known, or same time point
35 (36.8%
of 95)
14 (31.8%) 21 (41.2%)
Number of treatment courses administered for
granulomatous disease
117 (100%) 53 (45.3%) 64 (54.7%)DeCharacteristics of literature derived cohort. Percentages are of relevant totals shown.TABLE 4 | Reported granuloma involvement per organ location.












total 141cember 2020 | VolumeMultiple organs can be affected per patient; thus, in 95 patients, 141 granuloma locations
were scored.11 | Article 606389
van Stigt et al. Effective Treatment for Granulomatous CVIDHowever, various studies reported relapse of granulomatous
disease after discontinuation or termination of steroid therapy,
in both the CVID+EGD (17, 30, 34, 39, 51, 52) and CVID+PGD
(39, 42, 47, 48, 53, 54) group.
Infliximab and Etanercept
In CVID+EGD cases, the TNF-a inhibitor infliximab was the
third most frequently reported treatment regimen (six out of 53
treatment courses) (Table 5). Infliximab as monotherapy was
always associated with remission (Table 5) (28, 30, 33, 55). In four
out of six patients, infliximab was used to treat granulomatous
disease of the skin (28, 30, 33, 55). One study reported a treatment
regimen of steroids with infliximab for granulomatous disease of
the eye, which did not result in remission of granulomatous
disease (37). In CVID+PGD, infliximab was less frequently
reported as monotherapy (two out of 64 treatment courses), and
in one patient infliximab was administered in combination with
IgRT (Table 6) (54, 55). These three treatment courses were
associated with remission in the CVID+PGD group.
Etanercept, also interfering in the TNF-a signaling cascade,
was described only in CVID+EGD (three out of 53 treatment
courses) (Table 5). All three cases suffered from granulomatous
disease of the skin without other organ involvement (18, 56, 57).
All treatment courses with etanercept were associated with
remission in CVID+EGD.
Rituximab With or Without Azathioprine
Both rituximab and azathioprine were rarely administered in the
CVID+EGD group (Table 5). Only two cases with either
rituximab or azathioprine were described. One study reported
rituximab in combination with steroids in the CVID+EGD
group, which was associated with remission of extrapulmonary
granulomatous disease of the kidney (Tables 4 and 5) (58).
Another study reported a patient with granulomatous disease ofFrontiers in Immunology | www.frontiersin.org 6the skin, where steroids with azathioprine were administered;
this was associated with remission of granulomatous disease
(Tables 4 and 5) (52). Within the CVID+PGD group, the
combination of rituximab with azathioprine was the second
most frequently reported treatment regimen (12 out of 64
treatment courses), and was associated with remission in 11 of
the 12 treatment courses (91.7%) (Table 6) (49, 59–62). Also,
two treatment courses in the CVID+PGD were reported where
steroids formed part of the treatment regimen together with
rituximab and azathioprine (63, 64), and one where azathioprine
was given with steroids (65). All of these treatment courses were
considered effective as treatment for granulomatous disease.
Rituximab as monotherapy was the third most frequently
reported treatment regimen in CVID+PGD (six out of all 64
treatment courses), and the third most frequent treatment
regimen associated with remission (six out of 51 treatment
courses associated with remission) (Table 6) (66–68). All
described treatment courses of rituximab monotherapy for
CVID+PGD were effective (Table 6). In 20 of the 22 patients
with CVID+PGD were rituximab was part of treatment regimen,
granulomatous disease was only present in the lungs
(Supplemental Table 4) (49, 59–64, 66–69). In the majority of
the included cases the dose of rituximab as part of combination
therapy with azathioprine was consistent, namely 375 mg/m2
(49, 59, 60, 62). However, the duration of therapy when
retrievable varied greatly, from one time administration to 4
weeks or 6 months of treatment.
Immunoglobulin Replacement Therapy
We observed IgRT monotherapy to be the second most
frequently prescribed treatment regimen for CVID+EGD (six
out of 53 treatment courses). Three out of the six treatment
courses were associated with remission (Table 5) (39, 70–73). In
the CVID+PGD group, IgRT monotherapy was also reported, ofTABLE 5 | Treatment regimen and number of treatment courses administered in CVID+EGD group.




steroids 21 18 (85.7%) 3 (14.3%)
IgRT 6 3 (50%) 3 (50%)
infliximab 6 6 (100%) 0 (0%)
steroids with IgRT 4 4 (100%) 0 (0%)
etanercept 3 3 (100%) 0 (0%)
anti-mycobacterial therapy 1 0 (0%) 1 (100%)
adalimumab 1 0 (0%) 1 (100%)
antibiotics with steroids 1 0 (0%) 1 (100%)
antibiotics, anti-fungal therapy, steroids, cyclosporine, hydroxychloroquine, IFN-g, MTX 1 0 (0%) 1 (100%)
cyclophosphamide 1 1 (100%) 0 (0%)
cyclosporine 1 1 (100%) 0 (0%)
IFN-alpha with anti-mycobacterial therapy 1 1 (100%) 0 (0%)
MMF 1 1 (100%) 0 (0%)
steroids with anti-mycobacterial therapy 1 0 (0%) 1 (100%)
steroids with azathioprine 1 1 (100%) 0 (0%)
steroids with infliximab 1 0 (0%) 1 (100%)
steroids with methotrexate 1 1 (100%) 0 (0%)
steroids with rituximab 1 1 (100%) 0 (0%)
Total 53 41 12December 2020IgRT, immunoglobulin replacement therapy; IFN, interferon; MTX, methotrexate; MMF, mycophenolate mofetil. Percentages are of total number of treatment courses per treatment regimen.| Volume 11 | Article 606389
van Stigt et al. Effective Treatment for Granulomatous CVIDwhich four of the total five treatment courses were associated
with remission of granulomatous disease (Table 6) (64, 74–77).
The treatment regimen consisting of IgRT with steroids was
reported four times in CVID+EGD; all were associated with
remission of granulomatous disease (Table 5) (36, 39, 51).
Within the CVID+PGD group, steroids with IgRT was used in
six out of all 64 treatment courses, of which four were associated
with remission of pulmonary granulomatous disease (Table 6)
(36, 39, 50, 54, 78).
Other Treatment Regimen
The remaining therapeutic regimens reported in the included
articles were diverse, and low in frequency; most of these
treatment regimen had only one treatment course (Tables 5
and 6, Supplemental Table 4) (19, 33, 38, 39, 41, 48, 50, 52–54,
56, 57, 64, 78–83). Cyclophosphamide, cyclosporine,
hydroxychloroquine, methotrexate, mycophenolate mofetil,
among others were reported in our literature derived cases.
They were mainly administered in combination with other
immunosuppressive medication and generally associated with a
remission of granulomatous disease, for both CVID+PGD as
well as CVID+EGD.DISCUSSION AND CONCLUSION
Randomized controlled clinical trials for the treatment of
granulomatous disease in CVID are lacking. Currently,
attention for treatment of granulomatous disease in CVID has
mostly focused on GLILD (14). In 2017 the British lung
foundation and United Kingdom primary immunodeficiency
network published a consensus statement for the management
of GLILD in CVID based on the experience of 33 consultants
from the United Kingdom (14). It was proposed to use oral
steroids as first-line treatment, and azathioprine, rituximab, andFrontiers in Immunology | www.frontiersin.org 7mycophenolate alone or in combination with steroids as second-
line treatment. In this systematic review we summarized current
literature on the treatment of extrapulmonary granulomatous
disease and compared it to the treatment of pulmonary
granulomatous disease. We included CVID patients with
granulomatous disease in the lungs and excluded CVID
patients that had interstitial lung disease without granuloma.
Also, patients with known genetic variants were excluded, since
potential pathogenic pathways could be determined and specific
targeted therapies could be considered.
In about half of the CVID patients with granulomatous
disease, extrapulmonary involvement is found (3). Moreover,
besides lung granulomas, granulomas in the liver are associated
with reduced survival (3, 5). Within our literature derived cohort,
liver involvement was the fourth most frequently reported organ
involved in granulomatous disease. It is interesting to see that the
lungs and skin, two organs greatly exposed to the external milieu,
form the majority of organs affected by granulomatous disease in
the literature derived cases. Additionally, both in the CVID
+PGD and CVID+EGD cases, lymph nodes were the second
most frequently reported affected organs. This is similar to
previous other studies where anatomical locations of
granulomatous disease in larger patient series are reported (3, 8).
More than half of the 44 patients with CVID+EGD received
steroids as monotherapy or in combination with other therapies.
This is in line with the consensus statement on treatment of
GLILD by Hurst et al. (14). In the majority of patients, treatment
regimens with steroids appeared effective for treatment of
granulomatous disease. Also for the CVID+PGD group,
treatment regimens containing steroids were frequently
associated with remission of granulomatous disease. Lamers
et al. summarized the current literature on the treatment of
GLILD in CVID (Lamers et al., manuscript submitted). They
showed that steroids failed to induce remission in 57% of the
patients. This seems less effective than we have reported in thisTABLE 6 | Treatment regimen and number of treatment courses administered in CVID+PGD group.
Treatment regimen in CVID+PGD Total Treatment courses with remission Treatment courses without remission
steroids 15 10 (66.7%) 5 (33.3%)
rituximab with azathioprine 12 11 (91.7%) 1 (8.3%)
rituximab 6 6 (100%) 0 (0%)
steroids with IgRT 6 4 (66.7%) 2 (33.3%)
IgRT 5 4 (80%) 1 (20%)
MMF 3 3 (100%) 0 (0%)
anti-mycobacterial therapy 2 0 (0%) 2 (100%)
IgRT with MMF 2 2 (100%) 0 (0%)
infliximab 2 2 (100%) 0 (0%)
steroids with rituximab with azathioprine 2 2 (100%) 0 (0%)
cyclophosphamide 1 0 (0%) 1 (100%)
IgRT with infliximab 1 1 (100%) 0 (0%)
IgRT with methotrexate with hydroxychloroquine 1 1 (100%) 0 (0%)
IgRT with rituximab 1 1 (100%) 0 (0%)
rituximab with MMF 1 1 (100%) 0 (0%)
steroids with azathioprine 1 1 (100%) 0 (0%)
steroids with cyclophosphamide 1 1 (100%) 0 (0%)
steroids with cyclosporine 1 1 (100%) 0 (0%)
steroids with IgRT with anti-mycobacterial therapy 1 1 (100%)
64 51 13DeceIgRT, immunoglobulin replacement therapy; IFN, interferon; MMF, mycophenolate mofetil. Percentages are of total number of treatment courses per treatment regimen.mber 2020 | Volume 11 | Article 606389
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different search strategy and inclusion criteria. Secondly, Lamers
et al. included all CVID patients with GLILD, while we did not
include CVID patients that had interstitial lung disease without
granulomatous disease. Thirdly, we reported treatment as
effective when a treatment course was associated with
remission regardless whether the granulomatous disease
relapsed after termination of treatment. Lamers et al.
considered treatment effective only when there was relapse free
improvement of the granulomatous disease. These differences in
approach could explain the difference regarding efficacy of
steroid therapy for granulomatous disease with lung
involvement between the two reviews. Both studies observed
that discontinuation of steroid therapy could result in recurrence
of granulomatous disease. As reported in seven case reports
where steroids were administered as monotherapy, initial
association with remission of granulomatous disease was
observed, but not maintained after discontinuation of steroid
therpy (42). (17, 34, 47, 48, 51) These relapses after
discontinuation of steroid therapy suggest steroid monotherapy
not to have an sustained effect on granulomatous disease. This
indicates a potential need for long term therapy, or combination
therapy with other immunosuppressive therapy, to maintain
granulomatous remission. However, multiple side effects of
steroid therapy, together with the dilemma of administering
long term immunosuppressive therapy to an immune deficient
patient, underscore the need for more targeted, preferably
temporarily, therapeutic options.
Granulomatous disease is thought to be initiated, as yet by an
unknown trigger, by CD4+ T lymphocytes that, while interacting
with antigen presenting cells, become activated (84). Activated
CD4+ T lymphocytes secrete cytokines that subsequently
stimulate macrophage activation and TNF-a production,
ultimately leading to the characteristic immune cell agglomerates
(i.e. granulomas) in the involved organs. Like infliximab, etanercept
functions by interfering in the TNF-a signaling cascade. Therefore,
TNF-a is a theoretically promising cytokine to inhibit in the context
of granulomatous disease. Another encouraging finding is the
observed improvement of lung function in patients suffering from
pulmonary sarcoidosis after treatment with infliximab. However,
multiple adverse events are reported for infliximab and etanercept
when prescribed for other immune-mediated diseases, such as
increased risk of (granulomatous) infections, especially
tuberculosis infections, malignancies, and dermatological
complications (85–87). Moreover, several cases are reported
where TNF-alpha antagonist therapy seemed associated with
sarcoid-like disease (88–91).Therefore, TNF-alpha inhibition,
although a logical choice for granulomatous disease, should be
considered with caution. Within the CVID+EGD patients,
infliximab and etanercept were the most frequently used targeted
therapies. Moreover, all the infliximab or etanercept based
treatment regimens were associated with remission of
extrapulmonary granulomatous disease, though the total number
of treatment courses with etanercept was limited. In the majority of
these cases, granulomatous disease was manifested in the skin (18,
28, 30, 33, 55–57). A beneficial effect of TNF-a inhibition onFrontiers in Immunology | www.frontiersin.org 8granulomatous skin disease is also observed in patients suffering
from sarcoidosis (92–94). An illustrative case series by Tuchinda
et al., presented three patients that received infliximab for
sarcoidosis of the skin showing substantial improvement, of
which one showed improvement on infliximab monotherapy.
Interestingly, all these patients had received previous treatment
with immunosuppressive medication, such as steroids,
hydroxychloroquine or methotrexate, without clear improvement
of lesions (92). The hypothesis of inhibiting granuloma formation
by inhibiting the effect of TNF-a either via infliximab or etanercept,
together with the observed relatively high association with
granuloma remission of this treatment regimen, is promising for
extrapulmonary granulomatous disease in CVID, especially
concerning granulomatous disease of the skin.
Other targeted treatment regimens that were reported, included
rituximab and azathioprine. Rituximab is a monoclonal antibody
targeting CD20 on B lymphocytes; binding to the Fc-domain
eventually results in apoptosis of B-lymphocytes. Rituximab is
used in various immune mediated or malignant diseases, and is
frequently prescribed in combination with azathioprine, a purine-
antagonist of DNA synthesis supposed to halt B- and T-lymphocyte
proliferation (95, 96). Of note, within the context of other
inflammatory diseases such as rheumatoid arthritis and irritable
bowel syndrome, adverse events are reported for rituximab and
azathioprine, such as increased risk for infections or malignancies
due to their immunosuppressive effects (97, 98). Also certain late
adverse events of rituximab, although rare, are reported (99). In
CVID, the administration of rituximab has been used effectively for
non-infectious complications such as ITP or AIHA (100), and also
for GLILD (96, 101). The therapeutic combination of rituximab
with azathioprine, is also reported to be beneficial for GLILD (49,
96). The use of rituximab or azathioprine, together with steroids and
both effective, was only reported in two patients in the CVID+EGD
patients. This is in contrast to what we observed in the CVID+PGD
patients, where a treatment regimen of rituximab with azathioprine
was the second most frequently reported treatment regimen, and
most frequently associated with remission of granulomatous
disease. The observed beneficial effect of rituximab and
azathioprine for pulmonary granulomatous disease is in line with
recent reports on the treatment of GLILD (14, 96). Importantly, the
recent paper by Verbsky et al., not included in our analysis because
of publication date, showed that rituximab-containing therapeutic
regimens improved pulmonary function and radiographic
abnormalities in CVID patients with GLILD (96). Rituximab and
azathioprine, with the addition of steroids, could be beneficial in
CVID+EGD cases, since both included studies reported remission
of disease in CVID+EGD patients (52, 58). Due to the limited
number of patients treated with rituximab and/or azathioprine
CVID+EGD, their effects remain to be elucidated in CVID+EGD.
We found several reports with IgRT as, or as part of, therapy
for granulomatous disease (36, 39, 50, 51, 54, 64, 70–78, 102).
Since IgRT is the corner stone of treatment in CVID, this
treatment regimen is the hardest to judge for being associated
with remission of granulomatous disease. The reason for this is
twofold. Firstly, as this mode of therapy is considered standard of
care, IgRT was not always specifically reported in the includedDecember 2020 | Volume 11 | Article 606389
van Stigt et al. Effective Treatment for Granulomatous CVIDarticles, and can therefore be missed as part of treatment
regimens with other therapeutic interventions in our literature
cohort. On the other hand, not every CVID patient has a need for
IgRT, making the absence of reported IgRT likewise hard to
judge. To address this problem, we decided to consider IgRT only
part of granulomatous disease treatment regimen if it was clearly
stated by the authors of the included article, or when IgRT was
started simultaneously with other treatment for granulomatous
disease as part of the treatment regimen. IgRT was sometimes
given as monotherapy, but also in combination with e.g. steroids.
Regarding previous work concerning IgRT in CVID, several
studies have been published. A beneficial role of IgRT for AI
complications has been illustrated by Wang et al., as they
observed less events of recurring autoimmune hemolytic
anemia (AIHA) and/or immune thrombocytopenic purpura
(ITP) after IgRT was initiated (22). However, the role of IgRT
for granulomatous disease remains debatable. Within our
included case reports, some authors stated IgRT to be
beneficial for granulomatous disease (70–72, 75–77). On the
other hand, the large study performed by Mechanic et al. did not
report an effect of intravenous IgRT on granulomatous disease
(7). Although it has to be mentioned that some of these patients
in the study by Mechanic et al. also received steroids, of which in
general no effect on granulomatous disease was reported likewise
(7). Taking all this into consideration, we believe IgRT to be an
essential part of standard treatment in CVID, of which the effect
on granulomatous disease remains to be clarified.
We attempted to elucidate treatment regimens and their
efficacy in patients with CVID and granulomatous disease with
an undefined genetic background. Although we actively excluded
cases where genetic variants were described, we cannot rule out
that included cases do have an unreported genetic variant
associated with CVID. In an increasing number of patients
with CVID, a genetic variant is found (1, 103, 104). In case a
genetic variant is known, potential pathogenic pathways could be
determined and specific targeted therapies could be considered.
As an example, the use of abatacept in patients with LRBA or
CTLA4 haploinsufficiency with granulomatous disease is
associated with improved clinical outcome, but has not been
reported in our analysis (105–107). Other known genetic
defects associated with a CVID phenotype, including RAG
deficiencies, may also influence therapeutic strategies (108,
109). For various genetically defined CVID patients with
GILD, such as CTLA4 or LRBA deficiency, also hematopoietic
stem cell transplantation (HSCT) has been described as
therapeutic option (110, 111).LIMITATIONS
Patients suffering from CVID with granulomatous disease, form
a heterogeneous and complex subgroup of this primary
immunodeficiency with a relatively rare complication. As
previously shown over decades, treatment regimens for
granulomatous disease are also heterogeneous (8, 23, 96, 112).
Only a limited number of manuscripts on the topic could beFrontiers in Immunology | www.frontiersin.org 9retrieved. Another limitation is, that mainly case reports or case
series were included, which are considered to be of the lowest of
scientific evidence. Additionally, it is also likely that mainly case
reports in which the treatment was associated with remission of
the granulomatous disease are published. Also, we actively
excluded literature cases were a genetic variant linked to CVID
was reported, thereby perusing to include only genetically
undefined CVID patients. However, genetic evaluation might
not always be performed in patients from the included articles.
Thereby, CVID patients with granulomatous disease and an
(unknown) genetic variant might be present in the performed
analysis. This is an important consideration to take into account
regarding interpretation of our findings. Additionally, it is
important to realize that information regarding duration of
remission of granulomatous disease by the discussed treatment
regimens is not well reported in the majority of the
included papers.FUTURE RECOMMENDATIONS
Ideally, large randomized controlled studies should be performed
with a long follow-up period, to objectively determine what are
the most effective treatment regimens in CVID+EGD or CVID
+PGD. However, due to the limited number of CVID patients
with granulomatous complications, setting up such a trial is
challenging. International clinical trials should be considered. As
illustrated by this review, and by the review of Lamers et al.,
evidence for deciding which treatment should be applied in
granulomatous disease is limited, contains heterogeneous
regimens, and is of limited scientific weight. However,
currently it seems the best possible way to determine
promising treatment options. We believe that the systematic
search of literature performed here could provide a valuable tool
for clinicians treating patients with granulomatous CVID,
especially regarding extrapulmonary involvement. Steroids
seem effective in the treatment of CVID+EGD. Although the
absolute number of reported targeted therapies, such as
infliximab, etanercept, rituximab and azathioprine, are low in
the CVID+EGD group, we believe these targeted therapies could
be of added value in treating extrapulmonary granulomatous
disease in CVID, as has also been described in CVID+PGD.DATA AVAILABILITY STATEMENT
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